104 results
Page 2 of 6
8-K
EX-10.1
bn8a 7uy11ww
7 Jul 21
Departure of Directors or Certain Officers
5:18pm
8-K/A
EX-99.2
x4flzc6 8wu2ltczhf4
1 Jul 21
Changes in Registrant's Certifying Accountant
4:44pm
424B3
s66xb9qbg0t6io
11 May 21
Prospectus supplement
5:19pm
8-K
EX-2.1
eq3d3aj92on
29 Mar 21
Tempest and Millendo Announce Proposed Merger Agreement
7:29am
425
EX-2.1
wdb 4gswl
29 Mar 21
Business combination disclosure
7:27am
8-K
2spp3 vt7fij7zn
28 Jan 21
Cost Associated with Exit or Disposal Activities
8:01am
8-K
EX-99.1
963zkvbcq2
5 Jan 21
Millendo Therapeutics Provides Pipeline and Business Update
9:08am
8-K
EX-99.1
i8e66 gj7hf
24 Sep 20
Millendo Therapeutics Announces Initiation of First-in-Human Clinical Trial of MLE-301, a Selective NK3R Antagonist
8:33am
8-K
EX-99.1
wkloladb7jwy 70fi
23 Jun 20
Millendo Therapeutics Provides Corporate and Pipeline Update
8:36am